History
Omega Laboratories Limited has been supplying its expertise to the
Canadian pharmaceutical industry for more than sixty years.
Canadian pharmaceutical industry for more than sixty years.
Present
FDA PAI is completed for new aseptic facility. The first injectable ANDA approval is received for the U.S. market.
2019
Launch of commercial batches for the Canadian market from the new aseptic facility.
2018
August 29th, 2016, Sagent Pharmaceuticals is acquired by Tokyo-based Nichi-Iko Pharmaceutical Co.
2016
October 1st, 2014, Sagent Pharmaceuticals Inc, a specialty pharmaceutical company, acquires Omega Laboratories Limited.
2014
Initiation of a significant expansion project for a new injectable manufacturing plant, a new quality-control laboratory and additional office space.
2013
High containment facility opens and launch of cytotoxic molecules.
2012
New agreements with several large international partners for marketing and distribution of Omega’s products for international markets.
2002/2004
Significant investment into injectable manufacturing infrastructure and product development team. Transformation into a manufacturer of generic injectable drugs.
2000/2002
Acquisition of Ondée Laboratories, makers and suppliers of sclerotherapy products.
1986
Acquisition of Hamon Laboratories and its injectable product manufacturing facility in Montreal.
1980
Omega Laboratories is established in Montreal and dedicated to offer a complete allergy service (diagnostic and desensibilization therapy).
1958
Connect with Us on
